Novartis (NVS) Market Capitalization, Earnings, Price, Holders
Symbol: NVS Rank: #39 Price: $104.52(0.06702%)

Market Cap: $221.5B($148.4M) Industry: Drug Manufacturers General Sector: Healthcare Country: Switzerland Insiders: 0.007% Institutions: 8.146%
Novartis AG Technicals

52 Week High: $104.52

52 Week Low: $74.09

50 Day MA: $89.32

200 Day MA: $85.1

52 Week Trading Range


Low: $74.09

High: $104.52

Daily Trading Range


Low: $103.945

High: $104.86

Market capitalization history for Novartis (NVS) in USD

As of December 2023, Novartis (NVS) has a market cap of $221.5 billion. Our data points out that NVS is ranked #39 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. NVS's market cap is 0.0670174% up from the last trading day.

NVS Statistics

Market Cap
Revenue TTM
Gross Profit TTM
Operating Margin TTM
Shares Outstanding
Shares Float
Trading Volume
P/E Ratio
PEG Ratio
Revenue Per Share
Dividend Per Share
Dividend Yield
Quote Type
Leaf logo
CDP Climate Change Score (NVS)

Latest News

Novartis (NVS) Shares Stats
Novartis (NVS) Valuation
Trailing P/E $26.4716
Forward P/E $14.5349
Price Sales TTM $3.7233
Price Book MRQ $3.2725
Enterprise Value $207,389,302,858
Enterprise Value Revenue $3.9682
Enterprise Value Ebitda $6.6563
Novartis AG Details

Address: Lichtstrasse 35

City: Basel

Zip: 4056

Phone: 41 61 324 1111


IPO Date: 1991-11-18

CEO: Dr. Vasant Narasimhan

Employees: 108,000

What is NVS about?

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.